对肠道屏障和粘膜免疫相关微生物群的向调节减弱了IgA脏病的进展
Ran Zhang1,2, Yuyan Tang3, Xiangru Feng1
1State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Gut microbes
|January 28, 2025
概括
IgA脏病 (IgAN) 与肠道微生物群的变化有关. 这项研究表明,在Igan模型中,基托醇糖 (COS) 可以恢复肠道屏障功能并减少损伤.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- IgA脏病 (IgAN) 的发病过程涉及肠道微生物群的失生.
- 肠道微生物群在IGAN启动和进展中的确切作用尚不清楚.
研究的目的:
- 调查IgAN对肠道微生物群组成和功能的影响.
- 阐明肠道微生物群触发的IGAN的机制.
- 评估Igan中的治疗潜力,以评估基托醇糖 (COS) 和COS配方 (COSF) 的治疗潜力.
主要方法:
- 使用IgA病 (IgAN) 和与人类微生物群相关的 (HMA) -IgAN小鼠模型.
- 分析了肠道微生物群的组成和多样性.
- 评估肠道屏障完整性 (紧密结合蛋白) 和免疫标记物.
- 管理COS和COSF以评估其影响.
主要成果:
- IgAN诱导了肠道微生物群的改变,减少了α多样性,改变了特定的细菌群 (例如,增加了Shigella sonnei,减少了Bifidobacterium pseudolongum).
- 观察到肠道B细胞不平衡和减少紧结蛋白 (ZO-1,Occludin).
- COS/COSF治疗丰富了有益的肠道细菌,增强了ZO-1表达,减少了APRIL/BAFF,并减轻了损伤.
结论:
- 在Igan中建立了清晰的-肠轴连接,通过肠道微生物群进行介导.
- 证明COS/COSF可以调节肠道微生物群,改善肠道屏障功能,并缓解Igan相关的病理.
- 提供了针对微生物群的饮食干预措施的证据,用于IGAN管理.
更多相关视频
14:18Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
1.7K
08:24Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
Published on: May 2, 2018
19.4K
相关概念视频
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
310
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
310
01:29Inflammatory Bowel Disease IV: Pharmacological Management
106
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
106
01:17Irritable Bowel Syndrome I: Introduction
240
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
240
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
131
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
131
01:30Inflammatory Bowel Disease II: Crohn's Disease
176
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
176